Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kwee Yong

Showing results (71-80 of 188) with videos related to

Pageof 19
Sort By:
Journal of the Peripheral Nervous System : JPNS|June 11, 2003
Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphomaMartin R Turner, Jason D Warren, Jean M Jacobs, et al.
British Journal of Haematology|October 22, 2016
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease responseArash Latifoltojar, Margaret Hall-Craggs, Neil Rabin, et al.
British Journal of Haematology|October 9, 2003
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusionsShirley D'Sa, Karl Peggs, Arnold Pizzey, et al.
European Journal of Haematology|January 9, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
British Journal of Haematology|August 21, 2018
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)Rakesh Popat, Sarah R Brown, Louise Flanagan, et al.
Leukemia & Lymphoma|June 24, 2021
Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patientsMarquita Camilleri, Thomas McGrath, William Wilson, et al.
British Journal of Haematology|September 17, 2013
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) TrialTreen C M Morris, Cathy Williams, Sue Bell, et al.
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
Haematologica|December 5, 2024
Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single-center, real-world experienceKe Xu, Charles Agbuduwe, Nickolaos Kanellias, et al.
Pageof 19

Showing results (71-80 of 188) with videos related to

Sort By:
Pageof 19
Journal of the Peripheral Nervous System : JPNS|June 11, 2003
Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphomaMartin R Turner, Jason D Warren, Jean M Jacobs, et al.
British Journal of Haematology|October 22, 2016
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease responseArash Latifoltojar, Margaret Hall-Craggs, Neil Rabin, et al.
British Journal of Haematology|October 9, 2003
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusionsShirley D'Sa, Karl Peggs, Arnold Pizzey, et al.
European Journal of Haematology|January 9, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
British Journal of Haematology|August 21, 2018
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)Rakesh Popat, Sarah R Brown, Louise Flanagan, et al.
Leukemia & Lymphoma|June 24, 2021
Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patientsMarquita Camilleri, Thomas McGrath, William Wilson, et al.
British Journal of Haematology|September 17, 2013
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) TrialTreen C M Morris, Cathy Williams, Sue Bell, et al.
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
Haematologica|December 5, 2024
Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single-center, real-world experienceKe Xu, Charles Agbuduwe, Nickolaos Kanellias, et al.
Pageof 19